Research
Canakinumab at the Recommended Dose Is Associated With Higher Rates of Long-Term Remission in Still’s Disease: Evidence From the AIDA Network Registry
New findings from the international AIDA Network Still’s Disease Registry suggest that canakinumab dosing in line with recommended posology may increase the likelihood of sustained remission and treatment discontinuation.
Link to article
A new study based on data from the international AIDA Network Still’s Disease Registry has been published in Frontiers in Pharmacology, providing further insights into the relationship between canakinumab dosing and long-term outcomes in patients with Still’s disease.
The analysis included 131 patients treated with canakinumab, comparing those receiving the recommended dose of 4 mg/kg every four weeks with patients receiving lower doses. Long-term remission was defined as sustained clinical inactive disease for at least six months, followed by treatment discontinuation.
Patients receiving canakinumab at the recommended dose showed a higher estimated probability of discontinuing treatment because of long-term remission, compared with those receiving lower doses (19% vs. 3.9%). The estimated difference was 15.1 percentage points, with a 98.4% posterior probability supporting the superiority of the recommended-dose strategy. This association remained consistent across different disease courses and age groups at disease onset.
These findings highlight the potential importance of appropriate canakinumab dosing in achieving sustained remission in Still’s disease. Once again, the AIDA Network registry demonstrates its value in generating international real-world evidence to support treatment optimization and improve long-term patient outcomes.